Related Experiment Videos
Biologic therapy for psoriasis: telephone triage
Daniel J Pearce1, Ann Boles, Heather M Greist
1Dermatology Resident, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Dermatology Nursing
|October 7, 2005
Summary
Biologics offer unparalleled efficacy for psoriasis treatment, though long-term safety and patient education remain key considerations for this advanced immune-mediated therapy.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Psoriasis treatment has advanced significantly over 15 years.
- Understanding psoriasis as an immune-mediated disease has driven new therapies.
- Traditional treatments like methotrexate and cyclosporine remain relevant.
Purpose of the Study:
- To review the advancements in psoriasis treatment, focusing on biologics.
- To discuss the efficacy, safety, and patient-related challenges of biologic therapies.
- To highlight the evolving patient-clinician-insurer relationship due to biologic costs.
Main Methods:
- Review of recent literature on psoriasis treatments.
- Analysis of the impact of biologics on psoriasis care.
- Discussion of patient education needs and barriers to biologic therapy.
Main Results:
- Biologics represent a novel class of injectable medications for psoriasis with high efficacy.
- Short-term safety data for biologics is promising, but long-term data is lacking.
- The high cost of biologics ($18,000-$30,000 annually) raises patient concerns and alters healthcare dynamics.
Conclusions:
- Biologics are transforming psoriasis management, offering new options for non-responders to traditional agents.
- Effective and safe use of biologics requires addressing patient understanding and comfort levels.
- Dermatology professionals, particularly nurses, must lead patient education efforts for optimal psoriasis care.